抗性高血压的四倍治疗与三倍治疗:QUADRO试验
Stefano Taddei1, Krzysztof Narkiewicz2, Stéphanie Bricout-Hennel3
1Department of Clinical and Experimental Medicine, University of Pisa, Via Roma 67, Pisa 56126, Italy.
与三重治疗相比,第一个全剂量四倍药片组合显著降低了耐药高血压患者的血压. 这为管理这种具有挑战性的疾病提供了更有效的治疗选择.
科学领域:
- 心脏病学 心脏病学
- 药理学 药理学是指药理学的学科.
- 临床试验 临床试验
背景情况:
- 抗性高血压与目标器官损伤,心血管疾病和死亡率的增加有关.
- 目前的指导方针建议将第四种药物添加到对失控血压 (BP) 的三重治疗中.
研究的目的:
- 为了评估第一个全剂量四倍单片组合 (SPC) 在降低血压的有效性,与三重抗高血压疗法相比.
- 为了评估不控制血压的患者的血压降低,尽管三重治疗.
主要方法:
- 进行了一项多中心,第三阶段,随机,受控,双盲试验 (QUADRO).
- 患有抗性高血压的参与者接受了四倍的SPC (百里诺普利尔/英达巴胺/安洛迪平/双醇) 或继续三倍治疗 (百里诺普利尔/英达巴胺/安洛迪平) 8周.
- 主要结局是8周办公室缩血压 (SBP) 降低;次要结局是24小时的门诊血压监测 (ABPM).
主要成果:
- 与三重治疗组相比,四重SPC组在办公室SBP (-8 mmHg) 和24小时ABPM (-8 mmHg) 中显著减少.
- 两种治疗方案都耐受良好,没有报告严重或严重的治疗出现的不良事件.
结论:
- 全剂量四倍SPC在降低血压方面表现出优越性,与三倍治疗相比.
- 这四重SPC代表了确诊耐药高血压患者的有效替代治疗方法.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
04:37Improved Home Blood Pressure Control by CT-guided Ozone-mediated Renal Denervation for Patients with Resistant Hypertension
Published on: June 6, 2025
相关概念视频
Hypertension IV: Drug Therapy and Lifestyle Modifications
Treatment for Pulmonary Arterial Hypertension: Oxygen Therapy for Respiratory Failure
Oxygen therapy is vital in increasing and maintaining blood oxygen levels in PAH patients. As a result, it aids in reducing fatigue,...
Trial and Error and Algorithm
Clinical Trials: Overview
Clinical Trials
There are four phases in a clinical trial. A phase one...
Scalar and Vector Triple Products
The scalar triple product is the dot product of a vector with the cross product of two vectors....
